Team:Wageningen UR
From 2012.igem.org
Line 78: | Line 78: | ||
<div class="achievement silver"> | <div class="achievement silver"> | ||
We characterised the stability [link work Mark] of CCMV VLPs. | We characterised the stability [link work Mark] of CCMV VLPs. | ||
- | <div class="achievement-desc">We changed the conditions in which the VLPs were | + | <div class="achievement-desc">We changed the conditions in which the VLPs were resuspended. By changing pH and temperature and taking samples over time, we indicated at which values the VLPs were not stable. This defines the borders at which the VLPs can be used.</div> |
</div> | </div> | ||
Revision as of 18:07, 20 September 2012
Abstract
A standardized tool for site specific drug delivery using Virus-Like Particles
Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.
The Constructor
An application that assists you in creating your cloning strategies for your iGEM project.